A Toothless Truce Lets Private Equity Off the Hook -By Fransiscus Nanga Roka

The recent announcement of a Federal Trade Commission settlement with U.S. Anesthesia Partners and Welsh, Carson, Anderson & Stowe should not be heralded as a victory for competition; rather it is a reminder that private equity can weaponize consolidation to suck the regulatory risk out of a practice area while emerging mostly intact.

Most antitrust standards would consider the overarching conduct brazen. Welsh Carson initially funded a systematic “roll-up” of almost two dozen premier anesthesia practices across Texas beginning in 2012, gobbling up some 1,000 physicians and 750 nurses such that USAP garnered the more than half of the state’s commercial anesthesia market. This was not growth propelled by clinical excellence. Market power that had been purchased with financial engineering, then exchanged for leverage over insurers who this whole time simply passed the costs on to patients by raising premiums and sending surprise bills. In its 2023 complaint, the FTC alleged that this mechanism constituted a substantial lessening of competition and unlawful monopolization in violation of the Sherman and Clayton Acts.

But glance at what the settlement itself really provides. The consent order is limited in duration to ten years, which may be good as a meaningful but temporally limited restraint (and which expires well before the market distortions it caused may reasonably unwind): under the FTC’s 2025 settlement with Welsh Carson, for instance, Welsh Carson will have to relinquish board control and obtain FTC approval on subsequent healthcare acquisitions. Even more worrisomely, Welsh Carson reached this result after successfully moving to dismiss the key allegations against it and then leveraging a favorable settlement position for which the government had already weakened its case.

The issue is compounded by USAP’s own resolution in April of 2026. No wrongdoing is admitted by the company, the actual terms remain confidential “to facilitate the negotiations USAP must comply with,” and enforcement hinges only on whether or not the FTC would rekindle litigation in case of noncompliance. This is not structural remedy. It is literally accountability postponed masquerading as a form of resolution. If the entity that constructed an empire based on monopoly status of hospital-based anesthesia providers in one of the biggest states in America can clean up without having to give away a single clinic, without acknowledging any culpability or wrong doing whatsoever and most importantly, without even revealing its own reform contract terms… The other private equity sponsors who salivate over physician staffing know: With risk comes reward; aggressive roll-ups are just a business risk.

The much deeper failure is actually one of structure rather than process. Vertical and horizontal consolidation in physician services exists precisely because anesthesia, emergency medicine, and radiology are markets where patients cannot make a meaningful choice — care is administered under duress, by often out-of-network providers not chosen by the patient. If regulators try to address this dynamic through litigation case-by-case, years after each roll-up is complete, they are always fighting the last war. When the FTC finally wins a remedy, even a partial one, monopoly rents are extracted and incorporated into years of insurance premiums.

But while the settlement offers no blueprint for avoiding such challenges down the road — only a slow-motion, negotiated accommodation to injury already done — what should worry observers of health care markets in both America and other jurisdictions facing similar pressures from corporatized medical practice (like Japan, South Korea, Canada or Indonesia) is that there isn’t any template for slowing or preventing such abuses. The FTC deserves credit just for actually going after the case, a real break from decades of laissez pas fair merger review in healthcare. But slap-on-the-cheek effort is not a competitive remedy fix. A real deterrent would involve proactively compelling divestitures, outright bans on future roll-ups and a requirement for clear and public settlement terms — not secret arrangements that allow the very companies alleged to have distorted healthcare cost to pen their own compliance playbook behind closed doors.

Fransiscus Nanga Roka

Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia